Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04370587 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
A Phase 1 study of Melanoma and Solid Tumor, sponsored by ImmVira Pharma Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 9
- Study locations
NCT04370587 is a Phase 1 study of Melanoma and Solid Tumor that is actively recruiting participants, run by ImmVira Pharma Co.. The registered enrollment target is 30 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (96% lower). The trial reports 9 study locations across 6 states.
The verdict
NCT04370587, a Phase 1 study of Melanoma and Solid Tumor, is actively recruiting participants, sponsored by ImmVira Pharma Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.
Conditions Studied
Interventions
- BIOLOGICAL T3011
- COMBINATION_PRODUCT T3011 + pembrolizumab
Study Locations (9)
Other
- Southern Oncology - Bedford Park
- Peninsula & South Eastern Haematology and Oncology Group - Frankston
- The Alfred - Melbourne
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Arizona
- Banner MD Anderson Cancer Center - Gilbert
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Texas
- Mary Crowley Cancer Research - Dallas
Virginia
- Virginia Cancer Specialists - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-09-17 |
| Est. Completion | 2027-01-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04370587
The ClinicalTrials.gov registry entry for NCT04370587 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (96% lower). The listed sponsor is ImmVira Pharma Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which T3011 is the first listed.
NCT04370587 reports 9 study locations spanning 6 distinct geographic areas - top geographies include Other, Massachusetts, Arizona.
Frequently Asked Questions
What is clinical trial NCT04370587 about?
NCT04370587 is a clinical study titled "A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors". This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.
What is the current status of trial NCT04370587?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2020-09-17. Estimated completion is 2027-01-10.
What conditions does trial NCT04370587 study?
This clinical trial studies the following conditions: Melanoma, Solid Tumor, Sarcoma, NSCLC, Squamous Cell Carcinoma.
What interventions are being tested in trial NCT04370587?
The interventions under investigation include: T3011 (BIOLOGICAL), T3011 + pembrolizumab (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04370587?
This trial is sponsored by ImmVira Pharma Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04370587 being conducted?
This trial has 9 study locations across Arizona, Massachusetts, Pennsylvania, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.